Feed/Investors/EQT Life Sciences

EQT Life Sciences

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on 2 rounds in the feed.

Rounds from 2025-06-11 to 2025-10-15

ROUNDS

led 1, joined 1

LED ROUNDS · USD

$67.5M

across 1 round · 1 co-led, split evenly

LATEST ROUND

Series C · $358.0M · 2025-10-15

CO-INVESTORS

named beside it

Rounds

[ 2 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers.	Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$358.0M	2025-10-15	[ PART ]
SpliceBio SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes.	Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$135M	2025-06-11	[ LEAD ]